Follow-Up Management for HBeAg-Negative Patients with Undetectable Viral Load

Current Disease Classification

The European Association for the Study of the Liver recommends that patients with HBeAg-negative chronic HBV infection, characterized by anti-HBe positivity, HBV DNA <2,000 IU/mL, and normal ALT levels, require lifelong monitoring every 6 months with ALT and HBV DNA testing, even with current undetectable viral load, as reactivation can occur 1, 2, 3
This phase is dynamic and can reactivate to an immune-active phase, requiring vigilant monitoring, with a risk of reactivation to HBeAg-negative chronic hepatitis if HBV DNA rises to ≥2,000 IU/mL with ALT elevation 4, 2

The American Association for the Study of Liver Diseases recommends ALT testing every 3-4 months to detect fluctuations that indicate reactivation, and HBV DNA measurement every 3-6 months using real-time PCR, as viral load can increase despite current undetectable levels 3, 2, 5, 6
The European Association for the Study of the Liver recommends HBsAg quantification every 6 months to monitor for potential HBsAg loss (functional cure), which occurs spontaneously in 1-3% per year in this phase 1, 2
After the first year, ALT testing should be performed every 6 months minimum, and HBV DNA measurement every 6 months to detect viral reactivation early 1, 2, 5, 7

The American Association for the Study of Liver Diseases recommends initiating ultrasound screening every 6 months immediately if the patient meets certain criteria, such as being an Asian male >40 years old, or having a family history of HCC, or any evidence of cirrhosis or advanced fibrosis 8, 1, 4
Even inactive carriers remain at risk for HCC, particularly if they have underlying fibrosis that developed before entering the inactive phase, with a substantial HCC risk if they have cirrhosis 1, 4

The European Association for the Study of the Liver recommends considering non-invasive fibrosis assessment (FibroScan/elastography or FIB-4/APRI scores) even with normal ALT and undetectable viral load, as patients with high FIB-4 or APRI suggesting advanced fibrosis (≥F2) have increased HCC risk despite being in the inactive phase 4, 2
If liver stiffness ≥9 kPa or significant fibrosis markers present, closer surveillance and potential treatment consideration may be warranted, with a risk of reactivation to HBeAg-negative chronic hepatitis if HBV DNA rises to ≥2,000 IU/mL with ALT elevation 1, 4

The American Association for the Study of Liver Diseases recommends immediately initiating prophylactic antiviral therapy if the patient requires immunosuppressive therapy, chemotherapy, or other immunosuppression, with antivirals started 2-4 weeks before immunosuppression and continued through treatment plus 12-24 months after completion 8

The European Association for the Study of the Liver recommends initiating antiviral therapy if monitoring reveals HBV DNA rises to ≥2,000 IU/mL with ALT elevation, or evidence of advanced fibrosis/cirrhosis on non-invasive testing, even with persistently low HBV DNA, or ALT persistently 1-2× ULN with HBV DNA >2,000 IU/mL 1, 4

The American Association for the Study of Liver Diseases recommends hepatitis A vaccination if anti-HAV negative, as coinfection increases mortality 5.6- to 29-fold, and screening for coinfections, such as anti-HCV, anti-HDV, and anti-HIV, and counseling on complete alcohol abstinence, as even limited consumption worsens outcomes 8

Inactive HBeAg‑negative chronic HBV infection (Phase 3) is defined by HBV DNA < 20 IU/mL, persistently normal ALT for ≥5 years, and a normal FibroScan that excludes significant fibrosis. 9
In this phase the risk of progression to cirrhosis or hepatocellular carcinoma (HCC) is low as long as the disease remains stable, but reactivation to active hepatitis B can occur, requiring vigilant surveillance. 10

The European Association for the Study of the Liver (EASL) 2017 guideline states that inactive carriers should not receive antiviral therapy because none of the treatment thresholds (HBV DNA ≥ 2,000 IU/mL, elevated ALT, or moderate‑to‑severe necroinflammation/fibrosis) are met. 9

Lifelong monitoring for inactive carriers should include ALT and HBV DNA testing every 6 months; HCC surveillance should be started when the individual is older than 40 years. 10

Ultrasound screening every 6 months is also indicated for individuals with a family history of HCC, irrespective of age. 9

Quantitative HBsAg < 1,000 IU/mL predicts a higher likelihood of spontaneous HBsAg loss and is associated with a favorable prognosis in inactive carriers. 9
Low quantitative HBsAg levels are linked to better clinical outcomes in this population. 10
Screening of household contacts and sexual partners for HBV serologic markers (HBsAg, anti‑HBc, anti‑HBs) and vaccinating those who are negative is recommended. 11
Testing for co‑infections (anti‑HCV, anti‑HDV, anti‑HIV) should be performed in inactive carriers. 11